Cargando…

Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin

INTRODUCTION: In spite of the multiple benefits of combination antiretroviral therapy (cART) on HIV positive patients, prolonged usage has been reported to exacerbate oxidative stress, and induce neurological and cognitive dysfunction, thus, the need to search for an adjuvant therapy to ameliorate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Akang, Edidiong N., Dosumu, Olufunke O., Afolayan, Olasunmbo O., Fagoroye, Adeola M., Osiagwu, Daniel D., Usman, Isilamiyat T., Oremosu, Ademola A., Akanmu, Alani S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488719/
https://www.ncbi.nlm.nih.gov/pubmed/31061913
http://dx.doi.org/10.1016/j.ibror.2019.04.002
_version_ 1783414697377136640
author Akang, Edidiong N.
Dosumu, Olufunke O.
Afolayan, Olasunmbo O.
Fagoroye, Adeola M.
Osiagwu, Daniel D.
Usman, Isilamiyat T.
Oremosu, Ademola A.
Akanmu, Alani S.
author_facet Akang, Edidiong N.
Dosumu, Olufunke O.
Afolayan, Olasunmbo O.
Fagoroye, Adeola M.
Osiagwu, Daniel D.
Usman, Isilamiyat T.
Oremosu, Ademola A.
Akanmu, Alani S.
author_sort Akang, Edidiong N.
collection PubMed
description INTRODUCTION: In spite of the multiple benefits of combination antiretroviral therapy (cART) on HIV positive patients, prolonged usage has been reported to exacerbate oxidative stress, and induce neurological and cognitive dysfunction, thus, the need to search for an adjuvant therapy to ameliorate the oxidative and improve treatment adherence with better virological outcome. This study aimed at determining the potential therapeutic effects of Quercetin and Naringenin on cART-induced cyto-architectural, neuro-behavioral and immunohistochemical changes in the hippocampus of the adult Wister rats. MATERIALS AND METHODS: The animals were grouped as follows: Control, DMSO, 24 mg/kg cART (Tenovovir 300 mg, Lamivudine 300 mg and Efavirenz 600 mg), 50 mg/kg Naringenin, 50 mg/kg Quercetin, cART + Naringenin, cART + Quercetin were administered orally for 8 weeks. At the end of administration, neurobehavioural test was conducted, animals were euthanized and hippocampus was processed for oxidative stress markers, histology, TNF-α, and Monoamine oxidase-B expression. RESULTS: At the end of 8 weeks of administration, 24 mg/kg cART decreased superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and increased Malondialdehyde (MDA). Whereas, 50 mg/kg quercetin, and 50 mg/kg Naringenin decreased the oxidative stress (increased SOD, CAT, GSH, and reduced MDA) induced by cART (reduced SOD, CAT, GSH, and increased MDA). In addition, hematoxylin and eosin stained hippocampus showed that quercetin and naringenin prevented neurodegenerative changes (marked cytoplasmic shrinkage and several pyknotic nuclei in the dentate gyrus and cornus ammonis regions) in cART-treated rats. Furthermore, immunohistochemical studies revealed that quercetin and naringenin attenuates cART-induced upregulation of monoamine oxidase-B (MAO-B) expression. Likewise, from the Morris water maze neurobehavioral studies, naringenin and quercetin also ameliorated cART-induced memory impairments (initial spatial memory, reversal spatial memory and probe tests). CONCLUSION: This study shows that Naringenin and Quercetin have a good potential in reversing cART-induced hippocampal disorders in Wistar rats.
format Online
Article
Text
id pubmed-6488719
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-64887192019-05-06 Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin Akang, Edidiong N. Dosumu, Olufunke O. Afolayan, Olasunmbo O. Fagoroye, Adeola M. Osiagwu, Daniel D. Usman, Isilamiyat T. Oremosu, Ademola A. Akanmu, Alani S. IBRO Rep Article INTRODUCTION: In spite of the multiple benefits of combination antiretroviral therapy (cART) on HIV positive patients, prolonged usage has been reported to exacerbate oxidative stress, and induce neurological and cognitive dysfunction, thus, the need to search for an adjuvant therapy to ameliorate the oxidative and improve treatment adherence with better virological outcome. This study aimed at determining the potential therapeutic effects of Quercetin and Naringenin on cART-induced cyto-architectural, neuro-behavioral and immunohistochemical changes in the hippocampus of the adult Wister rats. MATERIALS AND METHODS: The animals were grouped as follows: Control, DMSO, 24 mg/kg cART (Tenovovir 300 mg, Lamivudine 300 mg and Efavirenz 600 mg), 50 mg/kg Naringenin, 50 mg/kg Quercetin, cART + Naringenin, cART + Quercetin were administered orally for 8 weeks. At the end of administration, neurobehavioural test was conducted, animals were euthanized and hippocampus was processed for oxidative stress markers, histology, TNF-α, and Monoamine oxidase-B expression. RESULTS: At the end of 8 weeks of administration, 24 mg/kg cART decreased superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and increased Malondialdehyde (MDA). Whereas, 50 mg/kg quercetin, and 50 mg/kg Naringenin decreased the oxidative stress (increased SOD, CAT, GSH, and reduced MDA) induced by cART (reduced SOD, CAT, GSH, and increased MDA). In addition, hematoxylin and eosin stained hippocampus showed that quercetin and naringenin prevented neurodegenerative changes (marked cytoplasmic shrinkage and several pyknotic nuclei in the dentate gyrus and cornus ammonis regions) in cART-treated rats. Furthermore, immunohistochemical studies revealed that quercetin and naringenin attenuates cART-induced upregulation of monoamine oxidase-B (MAO-B) expression. Likewise, from the Morris water maze neurobehavioral studies, naringenin and quercetin also ameliorated cART-induced memory impairments (initial spatial memory, reversal spatial memory and probe tests). CONCLUSION: This study shows that Naringenin and Quercetin have a good potential in reversing cART-induced hippocampal disorders in Wistar rats. Elsevier 2019-04-24 /pmc/articles/PMC6488719/ /pubmed/31061913 http://dx.doi.org/10.1016/j.ibror.2019.04.002 Text en © 2019 The Author http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Akang, Edidiong N.
Dosumu, Olufunke O.
Afolayan, Olasunmbo O.
Fagoroye, Adeola M.
Osiagwu, Daniel D.
Usman, Isilamiyat T.
Oremosu, Ademola A.
Akanmu, Alani S.
Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title_full Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title_fullStr Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title_full_unstemmed Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title_short Combination antiretroviral therapy (cART)-induced hippocampal disorders: Highlights on therapeutic potential of Naringenin and Quercetin
title_sort combination antiretroviral therapy (cart)-induced hippocampal disorders: highlights on therapeutic potential of naringenin and quercetin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488719/
https://www.ncbi.nlm.nih.gov/pubmed/31061913
http://dx.doi.org/10.1016/j.ibror.2019.04.002
work_keys_str_mv AT akangedidiongn combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT dosumuolufunkeo combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT afolayanolasunmboo combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT fagoroyeadeolam combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT osiagwudanield combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT usmanisilamiyatt combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT oremosuademolaa combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin
AT akanmualanis combinationantiretroviraltherapycartinducedhippocampaldisordershighlightsontherapeuticpotentialofnaringeninandquercetin